Prevention and treatment of postmenopausal osteoporosis

Journal of Steroid Biochemistry and Molecular Biology

Volumn 142, Issue , 2014, Pages 155-170

  Tella, Sri Harsha ^a   Gallagher, J Christopher ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BMD; Diagnosis; Osteoporosis; Risk factors; Treatment

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CATHEPSIN K INHIBITOR; CYTOKINE; DENOSUMAB; ESTRADIOL VALERATE PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; IBANDRONIC ACID; LASOFOXIFENE; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; PROTEIN; RALOXIFENE; RISEDRONIC ACID; SCLEROSTIN; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE MARROW CELL; BONE REMODELING; BONE TURNOVER; BREAST CANCER; DIETARY INTAKE; FEMUR FRACTURE; FRACTURE REDUCTION; FRAGILITY FRACTURE; GASTROINTESTINAL IRRITATION; HEART INFARCTION; HORMONAL THERAPY; HUMAN; JAW OSTEONECROSIS; MICROFRACTURE; OSTEOLYSIS; OSTEOPENIA; PATHOPHYSIOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; REVIEW; RISK FACTOR; SPINE FRACTURE; WNT SIGNALING PATHWAY;

BMD; DIAGNOSIS; OSTEOPOROSIS; RISK FACTORS; TREATMENT;

AGED; AGED, 80 AND OVER; ALENDRONATE; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY; BONE REMODELING; CALCITONIN; DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPROTEGERIN; RANK LIGAND; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TERIPARATIDE;

EID: 84899900531     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2013.09.008     Document Type: Review

References (88)

1. R. Pacifici Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis J. Bone Miner. Res. 11 1996 1043 1051
2. B.L. Riggs, S. Khosla, and L.J. Melton III A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men J. Bone Miner. Res. 13 1998 763 773
3. L.C. Hofbauer et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption J. Bone Miner. Res. 15 2000 2 12
4. N.K. Shevde, A.C. Bendixen, K.M. Dienger, and J.W. Pike Estrogens suppress RANK ligand induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression Proc. Natl. Acad. Sci. U.S.A. 97 2000 7829 7834
5. J.R. Bullamore, R. Wilkinson, J.C. Gallagher, and B.E. Nordin Marshall DH effect of age on calcium absorption Lancet 2 September (7672) 1970 535 537
6. F. Albright, P.H. Smith, and A.M. Richardson Postmenopausal osteoporosis JAMA 116 1941 2465 2474
7. P.B. Rapuri, J.C. Gallagher, and G. Haynatzki Endogenous levels of serum estradiol and sex hormone binding globulin determine bone mineral density, bone remodeling, the rate of bone loss, and response to treatment with estrogen in elderly women J. Clin. Endocrinol. Metab. 89 October (10) 2004 4954 4962
8. S.R. Cummings, W.S. Browner, D. Bauer, K. Stone, K. Ensrud, S. Jamal, and B. Ettinger Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group N. Engl. J. Med. 339 1998 733 738
9. G.A. Greendale, M.F. Sowers, W. Han, M.-H. Huang, J.S. Finkelstein, C.J. Crandall, J.S. Lee, and A.S. Karlamangla Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health Across the Nation (SWAN) J. Bone Miner. Res. 27 1 2012 111
10. P. Garnero, E. Sornay-Rendu, F. Duboeuf, and P.D. Delmas Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study J. Bone Miner. Res. 14 September (9) 1999 1614 1621
11. World Health Organization Collaborating Centre for Metabolic Bone Diseases. FRAXA WHO Fracture Risk Assessment Tool. Available at: http://www.shef.ac.uk/FRAX/ (accessed 28.10.09).
12. K.L. Stone, D.G. Seeley, and L.Y. Lui et al. For the study of osteoporotic fractures research group. BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures J. Bone Miner. Res. 18 2003 1947 1954
13. E.S. Siris et al. JAMA 286 2001 2815 2822
14. R.L. Prince, A. Devine, S.S. Dhaliwal, and I.M. Dick Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women Arch. Intern. Med. 166 April (8) 2006 869 875
15. M.J. Bolland, A. Avenell, and J.A. Baron et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis BMJ 341 2010 c3691
16. R.P. Heaney, T.M. Zizic, and I. Fogelman et al. Risedronate reduces the risk of first vertebral fracture in osteoporotic women Osteoporos. Int. 13 6 2002 501 505
17. M.F. Holick Vitamin D deficiency N. Engl. J. Med. 357 3 2007 266 281
18. Writing Group for the women's health initiative investigators JAMA 288 2002 321 333
19. P.M. Sarrel, V.Y. Njike, V. Vinante, and D.L. Katz The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years Am. J. Public Health 103 September (9) 2013 1583 1588
20. J.C. Stevenson, N. Panay, and C. Pexman-Fieth Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety Maturitas 76 September (1) 2013 10 21 10.1016/j.maturitas.2013.05.018
21. G. Wells, P. Tugwell, B. Shea, G. Guyatt, J. Peterson, N. Zytaruk, V. Robinson, D. Henry, D. O'Connell, and A. Cranney Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women Endocr. Rev. 23 August (4) 2002 529 539
22. J.C. Gallagher Effect of estrogen on bone M.J. Favus, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 5th ed. 2006 American Society for Bone and Mineral Research Washington, DC 327 330
23. R. Lindsay, J.C. Gallagher, M. Kleerekoper, and J.H. Pickar Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women JAMA 287 2002 2668 2676
24. J.H. Pickar, I.T. Yeh, G. Bachmann, and L. Speroff Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy Fertil. Steril. 92 September (3) 2009 1018 1024
25. D.J. Torgerson, and S.E. Bell-Syer Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials JAMA 285 June (22) 2001 2891 2897
26. J.A. Cauley, J. Robbins, Z. Chen, S.R. Cummings, R.D. Jackson, A.Z. LaCroix, M. LeBoff, C.E. Lewis, J. McGowan, J. Neuner, M. Pettinger, M.L. Stefanick, J. Wactawski-Wende, and N.B. Watts Women's health initiative investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the women's health initiative randomized trial JAMA 290 13 2003 1729 1738
27. R.D. Jackson, J. Wactawski-Wende, A.Z. LaCroix, M. Pettinger, R.A. Yood, N.B. Watts, J.A. Robbins, C.E. Lewis, S.A. Beresford, M.G. Ko, M.J. Naughton, S. Satterfield, and T. Bassford Women's health initiative investigators. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial J. Bone Miner. Res. 21 6 2006 817 828
28. J.C. Gallagher, S.E. Fowler, and J.R. Detter et al. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss J. Clin. Endocrinol. Metab. 86 August (8) 2001 3618 3628
29. S.L. Greenspan, N.M. Resnick, and R.A. Parker Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial JAMA 289 May (19) 2003 2525 2533
30. A.J. Huang, B. Ettinger, and E. Vittinghoff et al. Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women J. Bone Miner. Res. 22 November (11) 2007 1791 1797
31. J.W. Nieves, L. Komar, and F. Cosman Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis J. Clin. Endocrinol. Metab. 86 May (5) 2001 1890 1897
32. S. Eviö, A. Tiitinen, and K. Laitinen et al. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis Am. J. Clin. Nutr. 67 January (1) 1998 18 24
33. S.T. Harris, E.F. Eriksen, and M. Davidson Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women J. Clin. Endocrinol. Metab. 89 February (2) 2004 626 631
34. R. Lindsay, J.C. Gallagher, R. Kagan, J.H. Pickar, and G. Constantine Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women Fertil. Steril. 93 3 2009
35. R.D. Wasnich, Y.Z. Bagger, and D.J. Hosking et al. Changes in bone density and turnover after alendronate or estrogen withdrawal Menopause 11 November-December (6 (Pt 1)) 2004 622 630
36. R. Karim, R.M. Dell, D.F. Greene, W.J. Mack, et al., Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization.
37. J.E. Manson, J. Hsia, and K.C. Johnson et al. Estrogen plus progestin and the risk of coronary heart disease N. Engl. J. Med. 349 2003 523 534
38. M.J. Stampfer, G.A. Colditz, and W.C. Willett et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study N. Engl. J. Med. 325 1991 756 762
39. F. Grodstein, J.E. Manson, and M.J. Stampfer Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation J. Womens Health (Larchmt) 15 35 2006 44
40. M.R. McClung, R.D. Wasnich, and D.J. Hosking et al. Prevention of postmenopausal bone loss: six-year results from the early postmenopausal intervention cohort study J. Clin. Endocrinol. Metab. 89 2004 4879 4885
41. M.J. Hooper, P.R. Ebeling, and A.P. Roberts et al. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebocontrolled trial Climacteric 8 2005 251 262
42. L. Mortensen, P. Charles, and P.J. Bekker et al. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up J. Clin. Endocrinol. Metab. 83 1998 396 402
43. M.R. McClung, R.D. Wasnich, and R. Recker et al. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis J. Bone Miner. Res. 19 2004 11 18
44. L.B. Tanko, D. Felsenberg, and E. Czerwinski et al. Oral weekly ibandronate prevents bone loss in postmenopausal women J. Intern. Med. 254 2003 159 167
45. M. McClung, P. Miller, and C. Recknor et al. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial Obstet. Gynecol. 114 2009 999 1007
46. D.M. Black, S.R. Cummings, and D.B. Karpf et al. Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Lancet 348 1996 1535 1541
47. D.M. Black, A.V. Schwartz, and K.E. Ensrud et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial JAMA 296 2006 2927 2938
48. S.T. Harris, N.B. Watts, and H.K. Genant et al. Vertebral Efficacy With Risedronate Therapy (VERT) study group. Effects of risedronate treatment on vertebral and non- vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial JAMA 282 1999 1344 1352
49. J. Reginster, H.W. Minne, and O.H. Sorensen et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos. Int. 11 2000 83 91
50. D.M. Black, P.D. Delmas, and R. Eastell et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N. Engl. J. Med. 356 2007 1809
51. D.M. Black, I.R. Reid, and S. Boonen et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) J. Bone Miner. Res. 27. 2 2012 243
52. C.H. Chesnut III, A. Skag, and C. Christiansen et al. Effects of oral ibandronate administered daily or inter- mittently on fracture risk in postmenopausal osteoporosis J. Bone Miner. Res. 19 2004 1241 1249
53. M.R. McClung, P. Geusens, and P.D. Miller et al. Hip intervention program study group. Effect of risedronate on the risk of hip fracture in elderly women N. Engl. J. Med. 344 2001 333 340
54. S. Khosla, D. Burr, and J. Cauley et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research J. Bone Miner. Res. 22 2007 1479
55. D.L. Diab, N.B. Watts, Use of drug holidays in women taking bisphosphonates. NAMS practice pearl.
56. M.O. Susan What is the optimal duration of bisphosphonate therapy? Clevel. Clin. J. Med. 78 9 2011 619 630
57. A. Cranney, P. Tugwell, and N. Zytaruk et al. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis Endocr. Rev. 23 2002 524
58. C.C. Johnston Jr., N.H. Bjarnason, and F.J. Cohen et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials Arch. Intern. Med. 160 2000 3444
59. E.E. Jolly, N.H. Bjarnason, and P. Neven et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years Menopause 10 2003 337 344
60. B. Ettinger, D.M. Black, and S.R. Cummings et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the more randomized trial. Multiple outcomes of raloxifene evaluation JAMA 281 1999 2189
61. P.D. Miller, A.A. Chines, and C. Christiansen Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study J. Bone Miner. Res. 23 4 2008 Apr 525 535
62. S.L. Silverman, A.A. Chines, and D.L. Kendler et al. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study Osteoporos. Int. 23 January (1) 2012 351 363
63. L. Xu, K.S. Tsai, and G.S. Kim Efficacy and safety of bazedoxifene in postmenopausal Asian women Osteoporos. Int. 22 February (2) 2011 559 565
64. S.R. Cummings, K. Ensrud, and P.D. Delmas et al. Lasofoxifene in postmenopausal women with osteoporosis N. Engl. J. Med. 362 February (8) 2010 686 696
65. S.R. Cummings, J. San Martin, and M.R. McClung et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis N. Engl. J. Med. 361 2009 756
66. H.G. Bone, R. Chapurlat, and M.L. Brandi et al. The effect of 3 or 6 years of denosumab exposure in women with postmenopausal osteoporosis: results from the freedom extension J. Clin. Endocrinol. Metab. 2013 (Epub ahead of print)
67. C.H. Chesnut 3rd, S. Silverman, and K. Andriano et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group Am. J. Med. 109 September (4) 2000 267 276
68. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM 341781.pdf
69. R.M. Neer, C.D. Arnaud, and J.R. Zanchetta et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N. Engl. J. Med. 344 2001 1434
70. S.L. Greenspan, H.G. Bone, and M.P. Ettinger et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial Ann. Intern. Med. 146 2007 326
71. R. Eastell, T. Nickelsen, and F. Marin et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS) J. Bone Miner. Res. 24 2009 726
72. R. Lindsay, J. Nieves, and C. Formica et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis Lancet 350 1997 550
73. D.M. Black, S.L. Greenspan, and K.E. Ensrud et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis N. Engl. J. Med. 349 2003 1207 1215
74. J.S. Finkelstein, A. Hayes, J.L. Hunzelman, J.J. Wyland, H. Lee, and R.M. Neer The effects of parathyroid hormone, alendronate, or both in men with osteoporosis N. Engl. J. Med. 349 2003 1216 1226
75. D.M. Black, J.P. Bilezikian, and K.E. Ensrud et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis N. Engl. J. Med. 353 2005 555 565
76. J.N. Tsai, A.V. Uihlein, and H. Lee Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial Lancet 382 July (9886) 2013 50 56 10.1016/S0140-6736(13)60856-9
77. M.R. McClung, A. Balske, D.E. Burgio, et al., Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.
78. N. Binkley, M. Bolognese, A. Sidorowicz-Bialynicka, A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
79. X. Li, M.S. Ominsky, and K.S. Warmington et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis J. Bone Miner. Res. 24 2009 578
80. M.G. Murphy, K. Cerchio, and S.A. Stoch et al. Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women J. Clin. Endocrinol. Metab. 90 2005 2022
81. H.G. Bone, M.R. McClung, and C. Roux et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density J. Bone Miner. Res. 25 2010 937
82. R. Eastell, S. Nagase, and M. Ohyama et al. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the ocean study J. Bone Miner. Res. 26 2011 1303
83. Institute of Medicine 2011 Dietary reference intakes for calcium and vitamin D 2013 The National Academies Press Washington, DC
84. J.C. Gallagher, D. Goldgar, and A. Moy Total Bone Calcium in Normal Women: Effect of Age and Menopause Status J. Bone Min Res. 2 6 2011 491 496
85. J.A. Kanis et al. Osteoporos Int. 12 2001 989 995
86. J.A. Kanis et al. Osteoporos Int. 16 2005 581 589
87. S.R. Cummings et al. N engl J Med. 332 1995 767 773
88. A. Cranney et al. Endocr Rev. 23 2002 570 578